Compare IDEXX Laboratories, Inc. (IDXX) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Under Armour Inc Class A — how do they compare? IDEXX Laboratories, Inc. trades at $543.91 (market cap $43.58B), while Under Armour Inc Class A trades at $7.19 (market cap $3.11B). The key difference: IDEXX Laboratories, Inc. is far larger — about 14× Under Armour Inc Class A's market cap, and Under Armour Inc Class A is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | UAA | |
|---|---|---|
Market Cap | $43.58B | $3.11B |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $8.14 |
52-Week Low | $526.44 | $4.17 |
Enterprise Value | $44.48B | $4.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories trades at $552.46, down 2.64% today, with neutral technical signals but strong fundamental performance. The company maintains robust profitability with 24.63% net margins and has beaten earnings expectations for three consecutive quarters. Recent news highlights AI integration in medical devices and upcoming Q2 2026 results on August 4, 2026. The stock shows consistent revenue growth from $3.4B in 2022 to $4.3B in 2025.
Outlook remains positive given earnings momentum and analyst consensus, though elevated valuation ratios (P/E 41.49) pose risks. Key catalysts include Q2 earnings release and continued AI adoption in veterinary diagnostics. Primary risks involve competitive pressures and market volatility affecting premium valuations.
Under Armour (UAA) trades at $7.37, down 0.81% today, with mixed signals: technicals are bullish on moving averages but RSI suggests overbought conditions. Fundamentally, the company reported a net loss of $201.27M in 2025 with negative margins, though recent quarters showed earnings beats. Cash flow trends are volatile, with 2025 net cash outflow of $361.87M. News highlights include a new Dodge collaboration and upcoming Q1 2027 earnings on August 7, 2026.
The outlook remains challenging due to weak North American sales and margin pressure, but international growth offers some offset. Analyst consensus is cautious with a $5.96 price target below current levels. Key risks include consumer spending softness and high debt. For investors, stabilization in earnings and cost control are critical for a turnaround, though near-term headwinds persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
